SonoThera Presents New Data at ESGCT 2025 Demonstrating Expression of Full-Length Human Dystrophin Using Targeted, Ultrasound-Mediated Delivery to Treat Duchenne Muscular Dystrophy

|
|

It may soon be possible to produce full-length human dystrophin for Duchenne muscular dystrophy. SonoThera's Ultrasound-Mediated Delivery method could make dreams come true.

SonoThera, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the 32nd congress of the European Society of Gene and Cell Therapy being held October 7-10 in Seville, Spain.

The poster presentation focuses on treating Duchenne Muscular Dystrophy (DMD) with a full-length human dystrophin payload delivered to skeletal, heart and diaphragm muscles using SonoThera’s proprietary RIPPLETM ultrasound-mediated delivery (UMD) technology.

Ultrasound-Mediated Delivery

The new data demonstrates the ability of RIPPLETM to enable broad, highly targeted biodistribution of diverse payload formats without size restriction, to enable genetic medicines that can be re-dosed, and which are safe, well-tolerated, and cost-effective. – What is Ultrasound-Mediated Delivery Method?

- Follow Us -
DMD Warrior Whatsapp Channel

Full-Length Human Dystrophin

  • New data demonstrates the ability of UMD technology to deliver genetic medicines, allowing for full-length human dystrophin protein expression in skeletal, heart and diaphragm muscle tissue in murine and non-human primate (NHP) models.
  • Results show high levels of durable human dystrophin protein expression exceeding 50% of endogenous levels have been achieved in NHP.
  • Poster presentation spotlights SonoThera’s proprietary, nonviral, non-invasive approach using ultrasound-mediated delivery (UMD).

“Our new data continues to demonstrate the potential of ultrasound-mediated delivery of genetic medicines and its unique capabilities in treating complex diseases like Duchenne Muscular Dystrophy,” said Kenneth Greenberg, PhD, CEO of SonoThera. “In particular, the ability to deliver targeted, full-length human dystrophin to skeletal, heart and diaphragm muscles in a durable, safe, redosable and noninvasive manner shows how UMD can overcome all of the challenges of current gene therapy delivery options. We look forward to sharing these results at this year’s ESGCT congress.”

Read MoreClinical Trials for Duchenne (List of All Researches)

- Follow Us -
DMDWarrioR Instagram
SourceSonoThera
Add DMDWarrior as a preferred Google source to see more of our trusted coverage.

Disclaimer: No content on this site should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

LEAVE A REPLY

Please enter your comment!
Please enter your name here


Trending on DMDWarrioR- Duchenne News

Related Articles